Post-earnings recap
Reported
Mon, Nov 9, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 6.91%. The lack of revenue data leaves some uncertainty, but management's comments suggest they are focused on their clinical development efforts. Investors may view the EPS beat as a sign of progress in the company's financial health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +22.87% |
| Revenue | N/A | N/A | N/A |
Management remains cautiously optimistic about their future prospects. They emphasized their commitment to advancing their clinical programs.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts in their clinical programs.